With every advancement in ADC development comes broadened possibilities for improving the state of cancer care. This year’s World ADC London conference focuses on maximizing the therapeutic index and bringing these transformative therapies to wider patient populations. Catch Jamie Rich, Senior Director, Technology, ADC Therapeutics Group on Tuesday, March 4 at 6 p.m. GMT for a presentation centered on the impact of antibody-drug conjugate design philosophy across topoisomerase ADCs. Learn more: https://lnkd.in/eVkYdzm #WorldADC
Zymeworks Inc.
Biotechnology Research
Vancouver, BC 29,506 followers
Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.
About us
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251 planned for 2025.
- Website
-
http://www.zymeworks.com
External link for Zymeworks Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Vancouver, BC
- Type
- Public Company
- Founded
- 2003
- Specialties
- antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
Locations
-
Primary
Get directions
114 E 4th Avenue
Suite 800
Vancouver, BC V5T1G4, CA
Employees at Zymeworks Inc.
-
Daniel Dex
Senior Vice President, Corporate Secretary and General Counsel at Zymeworks Inc.
-
Derek Miller
Life sciences executive, board member, consultant and mentor with a successful track record of 25+ years across Corporate Development, Business…
-
Carlos Campoy
Independent Board Director • Retired Public Company CFO • Qualified Financial Expert • Audit Chair • Nominating & Governance • Strategic Finance •…
-
Lindsey Foulkes, PhD
VP Corporate Development
Updates
-
ADCs have rapidly taken the center stage for dealmaking and oncology research and development partnerships. As more biopharma and biotech companies specializing in ADCs are formed, questions arise on how innovation, data, and risk-taking influence partnerships, licensing deals and investments across the industry. Hear from Lucas Donigian, Vice President and Head of Business Development and Commercial, as he joins other esteemed panelists on Monday, March 3 at 3 p.m. GMT to discuss the risks, rewards, and realities behind recent deals in the ADC field. Learn more: https://lnkd.in/eVkYdzm #WorldADC
-
-
Are you passionate about Clinical Quality Assurance and ready to take the next step in your career? We're looking for a Clinical Quality Assurance Manager to join our team and play a critical role in ensuring the highest standards in clinical research. 📍 Location: Redwood City or Bellevue 📌 What You’ll Do: • Support Clinical QA strategy & compliance in alignment with regulations • Build strong partnerships with internal teams & external CROs to support clinical programs • Provide strategic quality guidance on key initiatives … and more! Learn more and view other current openings: https://lnkd.in/gQfH8-Rr #Hiring #LifeSciences #BioTech #Careers
-
-
Our management team will be attending and presenting at four investor conferences in March. Presentations and webcasts will be available on our website at https://lnkd.in/gzFaAHj6.
-
-
Behind the innovative progress we see happening in cancer medicine are collaboration and investments toward a better tomorrow. We’re happy to share that Lucas Donigian, Vice President of Business Development will participate in a panel session at B. Riley Securities Oncology & Radiopharma Conference this Friday. #Oncology #ResearchAndDevelopment
-
-
Our team is growing, and we’re looking for top talent to join us in shaping the future. If you're passionate about innovation and thrive in a collaborative environment, we’d love to hear from you! We’re currently hiring for: 🔹 Senior Site Reliability Engineer (Vancouver) 🔹 Research Associate I, In Vitro Biology (Vancouver) 🔹 Senior Research Associate II, In Vitro Biology (Vancouver) Learn more: https://lnkd.in/gQfH8-Rr #Hiring #VancouverJobs #Biotech #JobOpportunity
-
-
We’re excited to share that Leone Patterson and Dr. Nina E. Weisser will participate in a virtual fireside chat tomorrow, February 20 at 2:00 pm ET for Citi’s 2025 Virtual Oncology Leadership Summit. Access the webcast: https://lnkd.in/eRfJNmV9
-
-
We’re thrilled to attend and participate in World ADC London taking place March 3-6! This annual event unites hundreds of oncology-care industry leaders for knowledge sharing and community building. Curated to inform and inspire all across the field, this forum includes thought-provoking seminars and workshops along with poster presentations, networking gatherings, and plenary sessions. Our very own Lucas Donigian, Vice President of Business Development, and Dr. Jamie Rich, Senior Director, Technology, ADC Therapeutic Development are featured speakers at this year’s event. Learn more about WADC 2025: https://lnkd.in/eVkYdzm #WADC2025 #OncologyResearch #ADC #BioTech
-
-
The Zymework management team will report on fourth quarter and full year 2024 financial results during a conference call and webcast on March 5, 2025 at 4:30 pm ET. Executive leadership will also present corporate updates during the virtual event. Learn more: https://lnkd.in/gzFaAHj6
-
-
Zymeworks Inc. reposted this
Today, on International Day of Women and Girls in Science, we honor the brilliant minds, bold innovators, and trailblazing female leaders transforming the world through science, technology, engineering, and mathematics. At Zymeworks, we are proud to stand alongside the incredible women driving breakthroughs in biotherapeutics, pioneering new treatments for difficult-to-treat cancers, and inspiring the next generation of scientists. Join us as we continue to champion, empower, and elevate women in STEM! #WomenInSTEM #InternationalDayofWomenandGirlsinScience #IDWGS
-